Radioimmunoassay of Human Ligandin

Authors

  • Morris Sherman,

    1. University of Cape Town/Medical Research Council Liver Research Group and the Departments of Medicine and Pathology, University of Cape Town, Republic of South Africa
    Search for more papers by this author
  • Nathan M. Bass,

    1. University of Cape Town/Medical Research Council Liver Research Group and the Departments of Medicine and Pathology, University of Cape Town, Republic of South Africa
    Search for more papers by this author
  • John A. H. Campbell,

    1. University of Cape Town/Medical Research Council Liver Research Group and the Departments of Medicine and Pathology, University of Cape Town, Republic of South Africa
    Search for more papers by this author
  • Ralph E. Kirsch

    Corresponding author
    1. University of Cape Town/Medical Research Council Liver Research Group and the Departments of Medicine and Pathology, University of Cape Town, Republic of South Africa
    • Professor Ralph E. Kirsch, University of Cape Town, Department of Medicine, Medical School, Observatory 7925, Republic of South Africa.
    Search for more papers by this author

Abstract

A sensitive and specific radioimmunoassay for human ligandin has been developed and used to study ligandin release into the serum in acute and chronic hepatitis. Serum ligandin concentrations were elevated in 67 of 68 cases of acute viral hepatitis. Ligandin levels frequently returned to normal within the first 2 weeks of illness. The rapid disappearance of ligandin preceded the return to normal of serum SGOT. In chronic active hepatitis, serum ligandin levels correlated significantly (p < 0.01) with histologic severity of disease. This correlation was not seen with SGOT. Serum ligandin may be useful in monitoring progress and the need for therapy in chronic active hepatitis.

Ancillary